Combination with other target agents, such as EGFR inhibitors, may represent a promising therapeutic strategy in specific areas (e.g., EGFR-TKI resistance), because HGF/c-MET pathway mediates VEGFR inhibitor resistance and vascular remodeling in NSCLC [18]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.